Three posters on November 14 and 15 compare the preclinical pill with orforglipron in animal models. Rivus says it plans to file an IND in Q1 2027.
Recap by typeshit. Full story at BioSpace.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
West Midlands Police and the UK regulator raided an industrial unit and also found packaging for around 30,000 more pens.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
Loading…